Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Pneumococcal 21-Valent Conjugate Vaccine Demonstrates Immune Response in Children 2 to <18 Years

Summary by contemporarypediatrics.com
Capvaxive was superior to PPSV23 for each of the 9 serotypes unique to Capvaxive and non inferior to PPSV23 for the 12 shared serotypes.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

contemporarypediatrics.comcontemporarypediatrics.com

Pneumococcal 21-valent conjugate vaccine demonstrates immune response in children 2 to <18 years

Capvaxive was superior to PPSV23 for each of the 9 serotypes unique to Capvaxive and non inferior to PPSV23 for the 12 shared serotypes.

Read Full Article
pharmatimes.compharmatimes.com

Capvaxive shows strong immune response in children at risk of pneumococcal disease

Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmatimes.com broke the news in on Thursday, September 11, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Merck icon

Merck

Lisbon, Portugal icon

Lisbon, Portugal

News
For You
SearchBlindspotLocal